• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ther Adv Respir Dis . Lung transplantation for severe COVID-19-related ARDS

tetano

Editor, Senior Moderator
Ther Adv Respir Dis


. Jan-Dec 2022;16:17534666221081035.
doi: 10.1177/17534666221081035.
Lung transplantation for severe COVID-19-related ARDS


Ryoung-Eun Ko[SUP] 1 [/SUP], Dong Kyu Oh[SUP] 2 [/SUP], Sun Mi Choi[SUP] 3 [/SUP], Sunghoon Park[SUP] 4 [/SUP], Ji Eun Park[SUP] 5 [/SUP], Jin Gu Lee[SUP] 6 [/SUP], Young Tae Kim[SUP] 7 [/SUP], Kyeongman Jeon[SUP] 8 [/SUP]



Affiliations

Abstract

Background: Lung transplantation (LT) is the gold standard for various end-stage chronic lung diseases and could be a salvage therapeutic option in acute respiratory distress syndrome (ARDS). However, LT is uncertain in patients with coronavirus disease 2019 (COVID-19)-related ARDS who failed to recover despite optimal management including extracorporeal membrane oxygenation (ECMO). This study aims to describe the pooled experience of LT for patients with severe COVID-19-related ARDS in Korea.
Methods: A nationwide multicenter retrospective observational study was performed with consecutive LT for severe COVID-19-related ARDS in South Korea (June 2020-June 2021). Data were collected and compared with other LTs after bridging with ECMO from the Korean Organ Transplantation Registry.
Results: Eleven patients with COVID-19-related ARDS underwent LT. The median age was 60.0 years [interquartile range (IQR), 57.5-62.5; six males]. All patients were supported with venovenous ECMO at LT listing and received rehabilitation before LT. Patients were transplanted at a median of 49 (IQR, 32-66) days after ECMO cannulation. Primary graft dysfunction within 72 h of LT developed in two (18.2%). One patient expired 4 days after LT due to sepsis and one patient underwent retransplantation for graft failure. After a median follow-up of 322 (IQR, 299-397) days, 10 patients are alive and recovering well. Compared with other LTs after bridging with ECMO (n = 27), post-transplant outcomes were similar between the two groups.
Conclusions: LT in patients with unresolving COVID-19-related ARDS were effective with reasonable short-term outcome.

Keywords: COVID-19; extracorporeal membrane oxygenations; frailty; lung transplantation; treatment outcome.
 
Back
Top Bottom